Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies
Language English Country Great Britain, England Media electronic
Document type Letter, Research Support, Non-U.S. Gov't
PubMed
34980142
PubMed Central
PMC8722310
DOI
10.1186/s12943-021-01445-0
PII: 10.1186/s12943-021-01445-0
Knihovny.cz E-resources
- MeSH
- Epigenesis, Genetic MeSH
- Epigenomics methods MeSH
- Humans MeSH
- Disease Management MeSH
- DNA Methylation * MeSH
- Disease Susceptibility MeSH
- Biomarkers, Tumor * MeSH
- Prostatic Neoplasms, Castration-Resistant blood diagnosis genetics therapy MeSH
- Prognosis MeSH
- Gene Expression Profiling MeSH
- Liquid Biopsy * methods MeSH
- Computational Biology methods MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Letter MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Biomarkers, Tumor * MeSH
Christian Doppler Laboratory for Applied Metabolomics Medical University of Vienna Vienna Austria
Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Clinical Pharmacology Medical University of Vienna Vienna Austria
Department of Health Economics Center for Public Health Medical University of Vienna Vienna Austria
Department of Pathology Medical University of Vienna Vienna Austria
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Medical University Vienna Vienna Austria
Department of Urology University of Texas Southwestern Medical Center Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
European Association of Urology Research Foundation Arnhem The Netherlands
Institute of Cancer Research Department of Medicine 1 Medical University of Vienna Vienna Austria
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Ludwig Boltzmann Institute Applied Diagnostics Vienna Austria
Unit of Laboratory Animal Pathology University of Veterinary Medicine Vienna Austria
See more in PubMed
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi: 10.3322/caac.21660. PubMed DOI
Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev. 2001;23:181–186. doi: 10.1093/oxfordjournals.epirev.a000787. PubMed DOI
Sumanasuriya S, Omlin A, Armstrong A, Attard G, Chi KN, Bevan CL, Shibakawa A, IJzerman MJ, De Laere B, Lolkema M, et al. Consensus statement on circulating biomarkers for advanced prostate cancer. Eur Urol Oncol. 2018;1:151–159. doi: 10.1016/j.euo.2018.02.009. PubMed DOI
Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, Tombal B, Gillessen S. clinicalguidelines@esmo.org EGCEa: prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1119–1134. doi: 10.1016/j.annonc.2020.06.011. PubMed DOI
Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG. Prostate cancer. Nat Rev Dis Primers. 2021;7:9. doi: 10.1038/s41572-020-00243-0. PubMed DOI
Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18:297–312. doi: 10.1038/s41571-020-00457-x. PubMed DOI
Lam D, Clark S, Stirzaker C, Pidsley R. Advances in prognostic methylation biomarkers for prostate cancer. Cancers. 2020;12(10):2993. PubMed PMC
Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM, Brooks JD, Myers RM, Sherlock G. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res. 2011;21:1017–1027. doi: 10.1101/gr.119487.110. PubMed DOI PMC
Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med. 2013;5:169ra110. doi: 10.1126/scitranslmed.3005211. PubMed DOI PMC
Beikircher G, Pulverer W, Hofner M, Noehammer C, Weinhaeusel A. Multiplexed and sensitive DNA methylation testing using methylation-sensitive restriction enzymes “MSRE-qPCR”. Methods Mol Biol. 2018;1708:407–424. doi: 10.1007/978-1-4939-7481-8_21. PubMed DOI
Bjerre MT, Norgaard M, Larsen OH, Jensen SO, Strand SH, Ostergren P, et al. Epigenetic analysis of circulating tumor DNA in localized and metastatic prostate cancer: evaluation of clinical biomarker potential. Cells. 2020;9. PubMed PMC
Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ, Whitlock NC, et al. Low abundance of circulating tumor DNA in localized prostate cancer. JCO Precis Oncol. 2019;3:PO.19.00176. PubMed PMC
Chen E, Cario CL, Leong L, Lopez K, Marquez CP, Chu C, Li PS, Oropeza E, Tenggara I, Cowan J, et al. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. Sci Rep. 2021;11:5040. doi: 10.1038/s41598-021-84507-z. PubMed DOI PMC
Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10:(466):eaat4921. PubMed PMC
Herman D, Leakey TI, Behrens A, Yao-Borengasser A, Cooney CA, Jousheghany F, Phanavanh B, Siegel ER, Safar AM, Korourian S, et al. CHST11 gene expression and DNA methylation in breast cancer. Int J Oncol. 2015;46:1243–1251. doi: 10.3892/ijo.2015.2828. PubMed DOI PMC
Powers E, Karachaliou GS, Kao C, Harrison MR, Hoimes CJ, George DJ, Armstrong AJ, Zhang T. Novel therapies are changing treatment paradigms in metastatic prostate cancer. J Hematol Oncol. 2020;13:144. doi: 10.1186/s13045-020-00978-z. PubMed DOI PMC
Currall BB, Chen M, Sallari RC, Cotter M, Wong KE, Robertson NG, Penney KL, Lunardi A, Reschke M, Hickox AE, et al. Loss of LDAH associated with prostate cancer and hearing loss. Hum Mol Genet. 2018;27:4194–4203. doi: 10.1093/hmg/ddy310. PubMed DOI PMC
Ilijazi D, Pulverer W, Ertl IE, Lemberger U, Kimura S, Abufaraj M, et al. Discovery of molecular DNA methylation-based biomarkers through genome-wide analysis of response patterns to BCG for bladder cancer. Cells. 2020;9:(8):1839. PubMed PMC
Khayami R, Hashemi SR, Kerachian MA. Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential. J Cell Mol Med. 2020;24:8890–8902. doi: 10.1111/jcmm.15581. PubMed DOI PMC
Lee HM, Hwang KA, Choi KC. Diverse pathways of epithelial mesenchymal transition related with cancer progression and metastasis and potential effects of endocrine disrupting chemicals on epithelial mesenchymal transition process. Mol Cell Endocrinol. 2017;457:103–113. doi: 10.1016/j.mce.2016.12.026. PubMed DOI
Moller M, Strand SH, Mundbjerg K, Liang G, Gill I, Haldrup C, Borre M, Hoyer S, Orntoft TF, Sorensen KD. Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients. Sci Rep. 2017;7:40636. doi: 10.1038/srep40636. PubMed DOI PMC
Pique L, de Paz Martinez A, Pineyro D, Martinez-Cardus A, Castro de Moura M, Llinas-Arias P, Setien F, Gomez-Miragaya J, Gonzalez-Suarez E, Sigurdsson S, et al. Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer. Oncogene. 2019;38:7106–7112. doi: 10.1038/s41388-019-0936-x. PubMed DOI
Vega-Benedetti AF, Loi E, Moi L, Blois S, Fadda A, Antonelli M, Arcella A, Badiali M, Giangaspero F, Morra I, et al. Clustered protocadherins methylation alterations in cancer. Clin Epigenetics. 2019;11:100. doi: 10.1186/s13148-019-0695-0. PubMed DOI PMC
Xu N, Wu YP, Ke ZB, Liang YC, Cai H, Su WT, Tao X, Chen SH, Zheng QS, Wei Y, Xue XY. Identification of key DNA methylation-driven genes in prostate adenocarcinoma: an integrative analysis of TCGA methylation data. J Transl Med. 2019;17:311. doi: 10.1186/s12967-019-2065-2. PubMed DOI PMC
Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers
